UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

FORM 8-K
 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 2, 2016

 

GUIDED THERAPEUTICS, INC.

 (Exact name of registrant as specified in its charter)

 

         

Delaware

(State or other jurisdiction of incorporation)

 

0-22179

(Commission File Number)

 

58-2029543

(IRS Employer Identification No.)

   

5835 Peachtree Corners East, Suite D

Norcross, Georgia

(Address of principal executive offices)

30092

(Zip Code)

           

 

Registrant’s telephone number, including area code: (770) 242-8723

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  [ ]

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  [ ]

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  [ ]

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

   
 

 

Item 1.01.           Entry into a Material Definitive Agreement.

 

On November 2, 2016, Guided Therapeutics, Inc. (the “Company”) entered into a Lockup and Exchange Agreement with GHS Investments, LLC (“GHS”), holder of approximately $221,000 in outstanding principal amount of the Company’s secured promissory note and all of the outstanding shares of the Company’s Series C convertible preferred stock (the “Agreement”).

Pursuant to the Agreement, upon the effectiveness of the 1:800 reverse stock split (see Item 8.01 to this current report) and continuing for 45 days after, GHS and its affiliates are prohibited from converting any portion of the secured promissory note or any of the shares of Series C preferred stock, or selling any securities of the Company that they beneficially own. In addition, the Company agreed that, upon consummation of its next financing, it would use $260,000 of net cash proceeds first, to repay GHS’s portion of the secured promissory note and second, with any remaining amount from the $260,000, to repurchase a portion of GHS’s shares of Series C preferred stock. In addition, GHS has agreed to exchange the stated value per share (plus any accrued but unpaid dividends) of its remaining shares of Series C preferred stock for new securities that we issue in the next qualifying financing we undertake on a dollar-for-dollar basis.

The above description is qualified in its entirety by reference to the Agreement, attached as Exhibit 10.1 to this current report and incorporated herein by reference.

Item 8.01.            Other Events.

 

On November 2, 2016, the Company amended its charter to provide for a 1:800 reverse stock split of all of its issued and outstanding common stock. The reverse stock split will be implemented prior to when trading opens on Monday, November 7, 2016.

The Company’s stockholders granted authority to the Board of Directors, in its discretion, to effect the Reverse Stock Split at at the 2016 annual meeting of stockholders held on September 23, 2016.

As a result of the reverse stock split, every 800 shares of issued and outstanding common stock of the Company is converted into 1 share of common stock. All fractional shares created by the reverse stock split are rounded to the nearest whole share. The number of the Company’s authorized shares of common stock does not change.

A new CUSIP number has been issued for the Company’s common stock (40171F303) to distinguish stock certificates issued after the reverse stock split. The pre-split CUSIP number was 40171F204.

The common stock will begin trading on a split-adjusted basis on the OTC under the ticker symbol “GTHPD”. The “D” is appended at the end of the ticker symbol to signify the reverse stock split for 20 trading days, at which time the symbol will revert back to “GTHP.”

The Company issued a press release, a copy of which is attached as exhibit 99.1, announcing the reverse stock split.

Item 9.01           Financial Statements and Exhibits

(d) Exhibits.

Number Exhibit
10.1 Lockup and Exchange Agreement, dated November 2, 2016, by the Company and GHS Investments, LLC
99.1 Press Release (Reverse Stock Split)

 

 

  2  
 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  

   GUIDED THERAPEUTICS, INC.
   
   By:       /s/ Gene S. Cartwright
   Name:  Gene S. Cartwright
    Title:    President and Chief Executive Officer
 Date:  November 4, 2016  

 

  3  
 

 

 

 

EXHIBIT INDEX

Number Exhibit
10.1 Lockup and Exchange Agreement, dated November 2, 2016, by the Company and GHS Investments, LLC
99.1 Press Release (Reverse Stock Split)

 

 

 

Exhibit 10.1

 

LOCKUP AND EXCHANGE AGREEMENT

 

This Lockup and Exchange Agreement (this “ Agreement ”) is made as of November 2, 2016 (the “ Effective Date ”) by GUIDED THERAPEUTICS, INC., a Delaware corporation (the “ Company ”), and GHS INVESTMENTS, LLC (“ GHS ” and, together with its affiliates, the “ GHS Parties ”).

 

GHS is the beneficial owner of 1,661 shares of the Company’s Series C Convertible Preferred Stock (“ Series C Stock ”) and $220,565.08 in principal outstanding balance of the Company’s Secured Promissory Note, originally issued pursuant to a Note Purchase Agreement dated September 10, 2014 between the Company and the original creditor(the “ Promissory Note ”).

 

For good and valuable consideration, the Company and GHS agree as follows:

 

1.                  Lockup . Effective upon an amendment to the Company’s certificate of incorporation providing for a 1:800 reverse stock split of the Company’s common stock, until the earlier of (a) 45 calendar days thereafter or (b) consummation of the Company’s next public offering of debt or equity securities (such offering, the “ Public Offering ” and such securities, the “ New Securities ”), no GHS Party shall convert into the Company’s common stock any portion of the Promissory Note or any shares of the Series C Stock that the GHS Party beneficially owns (notwithstanding any rights it may have to do so pursuant to the terms of the Promissory Note or the Series C Stock), nor shall any GHS Party transfer or agree to transfer any debt or equity of the Company that the GHS Party beneficially owns. Notwithstanding anything to the contrary in this Section 1, the restrictions on conversion or transfer of Company securities shall cease to be effective immediately upon the Company’s receipt of a notice of default from any third party holding indebtedness of the Company of an event of default under the terms of such indebtedness. The Company shall promptly notify GHS of any such receipt, provided that the timely filing of a current report on Form 8-K will serve as timely notification to GHS.

2.                  Partial Use of Proceeds from Public Offering . In the event that the Company consummates the Public Offering, then as promptly as practicable thereafter the Company shall use $260,000 of the cash proceeds from the Public Offering first, to repay in full all amounts due to the GHS Parties under the terms of the Promissory Note, and second, with any remaining portion of such $260,000, to repurchase the maximum number of whole shares of Series C Stock from GHS at their Stated Value (as defined in the certificate of designations governing the Series C Stock) that may be repurchased with all of such remaining portion.

3.                  Exchange . In the event that the Company consummates the Public Offering and raises at least $1,000,000, then, as promptly as practicable following the closing of the Public Offering (the “ Conversion Date ”) and the repurchase of Series C Stock and repayment of the Promissory Note, as provided in Section 2, each remaining outstanding share of Series C Stock that the GHS Parties hold as of the Conversion Date (the “ Surrendered Shares ”) shall be surrendered to the Company and exchanged for New Securities in accordance with the following formula:

NS = (SV + (MW – DV) + AF) ÷ OP

 

Where:

 

“NS” means the number of New Securities to be issued to the applicable GHS Party;

 

“SV” means the aggregate Stated Value (as defined in the certificate of designation governing the Series C Stock) of all Surrendered Shares;

 

“MW” means an amount equal to $420.00 for each Surrendered Share;

 

“DV” means the aggregate amount of quarterly dividends on the Surrendered Shares paid by the Company prior to the Conversion Date;

 

“AF” means the aggregate amount of any fees or liquidated damages then due and owing in respect of the Surrendered Shares; and

 

“OP” means the lowest price per security at which New Securities are issued to any party in the Public Offering (the “ Offering Price ”).

 

To the extent that the above provisions of this Section 3 would result in the issuance of a fractional New Security to a GHS Party, the Company shall select one of the following options: (i) issue such fractional New Security to such GHS Party, (ii) round the number of New Securities to be issued to such GHS Party up to the nearest whole number, or (iii) pay cash to such GHS Party in lieu of such fractional New Security, based on the Offering Price.

 

As investors in the New Securities, the GHS Parties shall be subject to investment terms not less favorable than those provided to any party in the Public Offering. Notwithstanding anything to the contrary in this Section 3, the GHS Parties shall have no obligation to exchange their shares of Series C Stock for New Securities unless the terms of the New Securities include a customary “downside price protection” provision automatically adjusting the conversion price of the New Securities downward to equal the offering price of any non-exempt offering of common stock (or equivalents) subsequent to the issuance of the New Securities, with such provision, with respect to any debt or warrants that may be offered as New Securities, to remain operative only until the common stock is listed on a national securities exchange, and with respect any preferred stock that may be offered as New Securities, to remain operative as long as such preferred stock is outstanding.

 

4.                  Consent . As a Lender (as defined in the Promissory Note) and Secured Party (as defined in the Security Agreement entered in connection with the issuance of the Promissory Note), GHS consents the transactions contemplated by this Agreement and, with respect to the $220,565.08 in outstanding principal amount it beneficially owns, represents and warrants that no further consent is necessary pursuant to the terms of the Promissory Note or Security Agreement with regard to the transactions contemplated by this Agreement.

5.                  Company Representations and Warranties . The Company has the requisite power and authority to enter into and perform its obligations under this Agreement. The execution and delivery of this Agreement by the Company and the consummation by the Company of the transactions contemplated hereby has been duly authorized. This Agreement has been duly executed and delivered by the Company and constitutes the legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms. The execution, delivery and performance by the Company of this Agreement, and the consummation by the Company of the transactions contemplated hereby will not (i) result in a violation of the organizational documents of the Company or (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancelation of, any agreement, indenture or instrument to which the Company is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws) applicable to the Company, except in the case of clauses (ii) and (iii) above, for such conflicts, defaults, rights or violations that would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the ability of the Company to perform its obligations hereunder.

6.                  GHS Representations and Warranties . GHS has the requisite power and authority to enter into and perform its obligations under this Agreement. The execution and delivery of this Agreement by GHS and the consummation by GHS of the transactions contemplated hereby has been duly authorized. This Agreement has been duly executed and delivered by GHS and constitutes the legal, valid and binding obligation of GHS, enforceable against GHS in accordance with its terms. The execution, delivery and performance by GHS of this Agreement, and the consummation by GHS of the transactions contemplated hereby will not (i) result in a violation of the organizational documents of GHS or (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancelation of, any agreement, indenture or instrument to which GHS is a party, or (iii) to GHS’s knowledge, result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws) applicable to GHS, except in the case of clauses (ii) and (iii) above, for such conflicts, defaults, rights or violations that would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the ability of GHS to perform its obligations hereunder. GHS beneficially owns $220,565.08 in outstanding principal amount of the Promissory Note free and clear of any liens (other than the obligations pursuant to this Agreement). Each share of Series C Stock beneficially owned by GHS is free and clear of any liens (other than the obligations pursuant to this Agreement).

7.                  Governing Law . This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York, regardless of the laws that might otherwise govern under applicable principles of conflicts of law.

8.                  Severability . If any provision of this Agreement is prohibited by law or otherwise determined to be invalid or unenforceable by a court of competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such provision shall not affect the validity of the remaining provisions of this Agreement so long as this Agreement as so modified continues to express, without material change, the original intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability of the provision(s) in question does not substantially impair the respective expectations or reciprocal obligations of the parties or the practical realization of the benefits that would otherwise be conferred upon the parties. The parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable provision(s).

9.                  No Third-Party Beneficiaries . This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other person.

10.              Cooperation . The parties agree to cooperate fully and execute any and all further documents and to take all additional actions which may be necessary or appropriate to give full force and effect to the basic terms and intent of this Agreement.

11.              Counterparts . This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party. Facsimile or .PDF signature pages shall be considered due execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original and not a facsimile or .PDF signature.

[Signature Page Follows]

 

   
 

 

 

 

[Signature Page to Lockup and Exchange Agreement]

 

The parties are signing this Agreement effective as of the date first written above.

 

 

GUIDED THERAPEUTICS, INC.

 

 

By: /s/ Gene S. Cartwright

Name: Gene S. Cartwright

Title: President

 

 

GHS INVESTMENTS, LLC

 

 

By: /s/ Safraz Harjee

Name: Safraz Harjee

Title: Member

 

 

Exhibit 99.1

 

FOR IMMEDIATE RELEASE

 

Guided Therapeutics Announces 1:800 Reverse Stock Split and Elimination of

“Toxic” Convertible Securities from its Balance Sheet

 

NORCROSS, GA (November 4, 2016) -- Guided Therapeutics, Inc. (OTCQB: GTHP) today announced a one-for-eight hundred (1:800) reverse split of its issued and outstanding common stock. The reverse stock split will be implemented when the market opens on Monday, November 7, 2016 and Guided’s common stock will begin trading on a split-adjusted basis at that time, with a “D” temporarily appended to the end of its ticker symbol for 20 business days to signify the split.

 

In addition, on November 2, 2016, Guided completed the last of a series of agreements with various holders of its convertible debt and equity securities to effectively eliminate the ability of those holders to convert their securities into common stock using a formula that relies on fluctuating market prices to determine the number of shares of common stock to be issued on conversion. Because these provisions can lead to dramatic stock price reductions and corresponding negative effects on stockholders, these types of securities have colloquially been called “toxic” convertibles. Going forward, all holders of Guided securities with such provisions have either exchanged, or agreed to exchange, those securities for securities with fixed-conversion formulas, which will effectively limit the reduction in earnings per share and proportional ownership that occurs when holders of convertible securities convert those securities into common stock.

 

“This exchange was the final piece in having all preferred stock and debt to be converted at a fixed price. This event marks an important milestone in the Company’s ability to fix its capital structure,” said Gene Cartwright, Guided Therapeutics CEO and President.

 

The reverse stock split affects all issued and outstanding shares of Guided’s common stock, as well as shares of common stock underlying stock options, warrants and convertible preferred stock outstanding immediately prior to the reverse stock split. Guided’s stockholders granted authority to the Board of Directors to effect the reverse stock split at the 2016 annual meeting of stockholders held on September 23, 2016.

 

Upon the reverse stock split, every 800 shares of issued and outstanding common stock is automatically converted into 1 share of common stock. Fractional shares are rounded up to a full share. The reverse stock split does not impact any stockholder’s percentage ownership or voting power, except for minimal effects resulting from the treatment of fractional shares. Following the reverse stock split, the number of outstanding shares of common stock is reduced by a factor of 800. There is no change in the number of authorized shares of common stock that Guided has authority to issue.

 

Computershare Inc. is acting as exchange agent for the reverse stock split. Stockholders holding their shares in book-entry form or through a bank, broker or other nominee do not need to take any action in connection with the reverse stock split, and will see the impact of the reverse stock split automatically reflected in their accounts. Beneficial holders may contact their bank, broker or nominee for more information. For those stockholders holding physical stock certificates, Computershare will send instructions for exchanging those certificates for shares held in book-entry form or for new certificates, in either case representing the post-split number of shares. Computershare can be reached at (800) 962-4284.

 

About Guided Therapeutics

Guided Therapeutics, Inc. (OTCQB: GTHP, temporarily GTHPD) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Company’s first product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial, with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. For more information, visit: www.guidedinc.com .

 

The Guided Therapeutics LuViva® Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use in the U.S. LuViva, the wave logo and “Early detection, better outcomes” are registered trademarks owned by Guided Therapeutics, Inc.

 

Forward-Looking Statements Disclaimer: This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and actual results may differ materially as a result of various risks and uncertainties. Other factors that could cause actual results to differ from those reflected in the forward-looking statements are set forth in the Company’s prior press releases and periodic public filings with the Securities and Exchange Commission, which are available via Guided’s website at www.guidedinc.com. The forward-looking statements in this press release are made as of the date of this press release and Guided does not undertake to revise or update these forward-looking statements, except to the extent that it is required to do so under applicable law

 

###END###

 

Investor and Media Relations Contact:

Bill Wells

Guided Therapeutics

770-242-8723